The immunoassay segment accounts about 35% of the market, with no growth compared to the previous year. Domestic brands account for over 35%.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Coriell Life Sciences and global professional services firm KPMG said today that they have entered into a partnership with to provide pharmacogenomics data to clinicians at the point of care. Thermo Fisher Scientific is contributing genetic

Expedeon reported today an 18 percent increase in second quarter revenues driven in part by sales generated by recently acquired reagent maker TGR Biosciences.

Bio-Techne said today that its fiscal 2019 fourth quarter revenues rose 6 percent over fiscal Q4 2018.

Revenues from BD's medical segment were $2.31 billion during the quarter, an increase of 3 percent from $2.25 billion last year driven by medication management solutions, medication delivery solutions, and pharmaceutical systems units.

Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services.

Biotechnology company Freenome and ADC Therapeutics, an oncology drug discovery and development company, announced today that they have signed a biomarker development agreement.

Cancer Genetics today reported a 15 percent increase in second quarter revenues on improved performance by its core discovery services operations.

Aqualung Therapeutics said on Tuesday that it has been awarded a $225,000 grant from the National Institutes of Health to develop a panel of biomarkers, called CRIT-ICU, for stratifying patients at risk for acute respiratory distress syndrom

10x Genomics is looking to raise up to $100 million in an initial public offering, according to documents filed Monday with the US Securities and Exchange Commission.

Agilent Technologies reported after the close of the market on Wednesday that its third quarter revenues rose 6 percent year over year, thanks largely to an 11 percent increase in revenues for its diagnostics and genomics business.